NanoViricides Files for Ebola Trial with Oral Gummies

NanoViricides, Inc. (NYSE American: NNVC) has announced a major step forward in the fight against Ebola, awaiting regulatory approval to begin a Phase II clinical trial of its NV-387 Oral Gummies for the treatment of Bundibugyo ebolavirus in the Democratic Republic of the Congo. The company submitted an application to the local regulatory agency and has secured financing to support the study, which aims to address the ongoing Ebola outbreak. Notably, no approved treatment or vaccine currently exists for the Bundibugyo strain, making this potential therapy a critical development. NanoViricides claims NV-387 is the only orally administered Ebola treatment candidate under consideration for clinical testing, and its broad-spectrum antiviral mechanism could offer significant advantages over infusion-based therapies in resource-limited outbreak settings. The company has already stockpiled sufficient quantities of the drug in the DRC to support the planned study, pending regulatory approval.

NanoViricides is a clinical-stage company specializing in creating special purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, is a broad-spectrum antiviral being developed for a range of viral infections, including RSV, COVID-19, Long COVID, Influenza, and even MPOX/Smallpox and Measles. The company's nanoviricide™ technology, based on intellectual property licensed from TheraCour Pharma, Inc., enables targeted antiviral delivery. Beyond Ebola, NanoViricides is also developing treatments for oral and genital Herpes, viral eye diseases, H1N1 swine flu, H5N1 bird flu, HIV, Hepatitis C, Rabies, Dengue fever, and more. The company holds exclusive licenses for several antiviral indications, positioning it as a key player in the fight against emerging viral threats.

The importance of this news cannot be overstated. With Ebola outbreaks occurring in regions with limited healthcare infrastructure, an oral treatment like NV-387 could revolutionize outbreak response by enabling easier distribution and administration compared to intravenous therapies. The Bundibugyo strain's lack of approved treatments underscores the urgency of this clinical trial. For investors, the progress of NV-387 represents a potential breakthrough in antiviral therapeutics, with broad applications beyond Ebola. However, as with all drug development, risks remain, including the lengthy and capital-intensive path to approval. The full press release is available at https://ibn.fm/t1kLC.